Key Design Considerations for Viral Clearance Validation Study Protocols of Gene Therapy Products

ICH Q5A(R2)-International Harmonization Foundation

ICH Q5A(R2) was officially adopted on November 1, 2023, and represents the core international guidance document for viral safety evaluation. Compared with Q5A(R1) published in 1999, the significant updates in the R2 version include: a newly added chapter on viral safety evaluation in continuous manufacturing (Chapter 7); a reinforced role of risk assessment as the foundation of viral clearance strategies; incorporation of next-generation sequencing (NGS) in viral detection considerations; and explicit requirements for the evaluation of novel products and manufacturing processes. Q5A(R2) has been adopted by regulatory authorities including FDA, EMA, and PMDA, providing a unified technical framework for viral clearance validation worldwide.

NMPA-Chinese Regulatory System

The NMPA regulatory framework for viral safety covers multiple levels:

Document Level	Document Name	Year of Issue
Foundational document	Technical Guidelines for Removal/Inactivation of Viruses from Blood Products	2002
Foundational document	General Principles for Technical Review of Viral Safety Evaluation of Biological Tissue-Derived Products and Eukaryotic Cell-Expressed Products	2005
Product-specific guideline	Technical Guidelines for Pharmaceutical Research and Evaluation of Clinical Trial Applications for Recombinant Adeno-Associated Virus (rAAV) Vector-Based In Vivo Gene Therapy Products	2023
Product-specific guideline	Common Technical Requirements for Pharmaceutical Quality of Recombinant Adeno-Associated Virus (rAAV) Vector-Based In Vivo Gene Therapy Products for Marketing Authorization Applications	2025
Innovative guideline	Technical Guidelines for Platform Validation of Viral Clearance Processes for Clinical Trial Applications of Therapeutic Recombinant Protein Products (Trial)a	2024

a: This guideline represents the first time the Chinese regulatory authority has set forth systematic technical requirements for platform validation of viral clearance processes, and is aligned with the spirit of ICH Q5A(R2).

FDA and EMA-US and European Regulatory Requirements

FDA formally issued an industry guidance document based on ICH Q5A(R2) in January 2024. In addition, the United States Pharmacopeia (USP) chapter <1050.1> provides supplementary technical guidance on the design, evaluation, and characterization of viral clearance procedures. FDA organizes a Viral Clearance Symposium every two years; the 2023 symposium addressed cutting-edge topics such as novel modalities, continuous manufacturing, novel chromatography media, and adsorptive filters. EMA's core guidance documents include CPMP/BWP/268/95 (Note for Guidance on Virus Validation Studies: The Design, Contribution and Interpretation of Studies Validating the Inactivation and Removal of Viruses) and EMEA/CHMP/BWP/398498/2005 (Guideline on Virus Safety Evaluation of Biotechnological Investigational Medicinal Products), both of which have been harmonized with ICH Q5A(R2).

Identification of Viral Contamination Sources

ICH Q5A(R2) emphasizes that the design of viral clearance validation should be based on a comprehensive risk assessment. For gene therapy products, identification of viral contamination sources should address the following levels:

Cell bank level: Endogenous viruses (e.g., retroviral particles) and latently infectious viruses potentially harbored in the production cell substrates (e.g., HEK293, CHO, HeLa). HEK293 cells are known to contain endogenous Ad5 E1 sequences and an approximately 900 bp EBV fragment, and are capable of expressing replication-competent adenovirus; therefore, particular attention should be paid to this risk in the risk assessment.

Helper virus level: AAV vector production typically employs methods such as triple transfection using helper plasmids, which carry the risk of generating replication-competent adenovirus (RCA). Similarly, packaging cells used in lentiviral vector production may generate replication-competent lentivirus (RCL).

Raw materials level: Adventitious viruses may be introduced through raw materials used in manufacturing, including cell culture media, feeds, and enzymes. This risk is particularly significant when animal-derived components are used (e.g., fetal bovine serum, trypsin digest solutions).

Risk Differences: Gene Therapy vs. Traditional Recombinant Proteins

Risk Dimension	Traditional Recombinant Protein Products	Gene Therapy Products
Viral source	Endogenous viruses from cell bank; adventitious viruses	Cell bank viruses; helper viruses; replication-competent vectors (RCV/RCL); host genome integration
Cell substrate	CHO, NS0, Sp2/0 and other well-characterized cell lines	HEK293, HeLa, CHO, etc.; some cell lines are of tumorigenic origin
Product characteristics	Protein-based drug; well-defined structure	Viral vector; poses biosafety risks
Validation strategy	Multi-step viral clearance; emphasis on process step validation	RCV/RCL detection required; validation and testing both essential
Platform validation	Applicable to established processes such as S/D, low pH, nanofiltration	Limited applicability due to diversity of vector types

Table 1. Comparison of Viral Safety Risks: Gene Therapy Products vs. Traditional Recombinant Protein Products

General Principles

Indicator virus selection is a central element in the design of viral clearance validation protocols. ICH Q5A(R2) requires that indicator virus selection be based on the risk assessment and take into account the following factors:

Relevance of the virus to the production cell substrate (relevant virus)

Physicochemical properties of the virus (enveloped/non-enveloped, DNA/RNA, size range)

Resistance of the virus to physical/chemical treatments

Detectability and biosafety of the virus

For gene therapy products, indicator virus selection must additionally consider: the role of the vector virus itself as a "relevant virus"; the potential risk of helper virus contamination; and the detection and validation requirements for replication-competent viruses (RCV/RCL).

Recommended Indicator Virus Panel

Virus	Type	Envelope	Genome	Size (nm)	Selection Rationale / Application
MVM	Parvovirus	None	ssDNA	18–26	Non-enveloped model; smallest size and highest resistance; suitable for nanofiltration validation (generally not applicable for rAAV vector products)
PPV	Parvovirus	None	ssDNA	18–26	Non-enveloped model; commonly used indicator virus for blood products
Reo-3	Reovirus	None	dsRNA	60–80	Non-enveloped model; medium size; high physical stability
PRV	Herpesviridae	Yes	dsDNA	150–200	Enveloped model; large size; broad host range
X-MuLV	Retrovirus	Yes	ssRNA	80–110	Enveloped retrovirus model; appropriate for CHO-derived cell substrates
BVDV	Flaviviridae	Yes	ssRNA	40–60	Enveloped model; used to evaluate chemical inactivation methods (HCV surrogate)
VSV	Rhabdoviridae	Yes	ssRNA	70	Enveloped model; broad pH tolerance; suitable for low-pH inactivation validation

Table 2. Recommended Indicator Virus Panel for Viral Clearance Validation of Gene Therapy Products

Special Considerations for AAV Vector Products

For recombinant AAV vector products, the NMPA Technical Guidelines for Pharmaceutical Research and Evaluation of Clinical Trial Applications for rAAV Vector-Based In Vivo Gene Therapy Products require attention to the detection of replication-competent AAV (rcAAV). rcAAV refers to AAV capable of autonomous replication, which typically arises from homologous recombination between the helper plasmid and the product AAV genome. Detection of rcAAV is generally performed using infectious assays or qPCR methods, conducted separately on the drug substance and the purified product.

It is worth noting that downstream purification processes for AAV vector products typically include nuclease digestion, chromatography (AEX), nanofiltration, and ion exchange chromatography (CEX/IEX). In traditional viral clearance validation, these process steps may result in significant losses of the AAV vector itself; therefore, the interaction between the vector and indicator viruses must be carefully considered during scale-down model design. For certain process steps (e.g., nanofiltration) where AAV vector losses are substantial, it should be evaluated whether process adjustments are warranted based on validation data (e.g., adjustment of nanofiltration membrane pore size).

General Principles

The scale-down model (SDM) is the core tool for viral clearance validation; its design must accurately represent the viral clearance performance of the manufacturing process. ICH Q5A(R2), Section 6.2.2, explicitly requires that the scale-down model maintain consistency with the manufacturing process in key parameters. For gene therapy products, the following considerations are especially important in SDM design:

Representativeness of Critical Process Parameters

The scale-down model should be consistent with the manufacturing process in the following parameters: chromatographic conditions (buffer composition, pH, conductivity); loading ratio (vector/supernatant protein mass ratio); contact time and temperature; flow rate/residence time; product purity and composition. For AAV products, the effect of vector particle size distribution and empty capsid content on nanofiltration performance should also be specifically addressed.

Model Qualification Requirements

ICH Q5A(R2) requires adequate qualification of the scale-down model, including: comparison of product quality attributes (e.g., purity, recovery, density); qualification of critical process parameter consistency; and ensuring the scale-down model captures process variability of the manufacturing process. For chromatography steps, the consistency of peak profile, elution, and wash should be qualified; for nanofiltration steps, the effects of volume capacity and product composition should be verified.

LRV Calculation Formula

The log reduction value (LRV) is the core metric for measuring viral clearance efficacy. ICH Q5A(R2), Section 6.5, provides a detailed description of LRV calculation methods and statistical treatment. The basic LRV calculation formula is: LRV = log₁₀(N₀/N), where N₀ is the initial virus titer after virus spiking and N is the residual virus titer after process treatment. When the residual virus titer falls below the detection limit of the assay, estimation methods such as the Poisson distribution should be used (e.g., large-volume testing).

Application of Confidence Intervals

Both ICH Q5A(R2) and EMA CPMP/BWP/268/95 require confidence interval assessment of LRV calculation results. A 95% confidence interval is typically applied.

Criteria for Effectiveness

According to the NMPA Technical Guidelines for Removal/Inactivation of Viruses from Blood Products, a virus reduction of ≥4 logs indicates that the process step is effective for virus removal/inactivation. However, this criterion is not an absolute threshold and should be evaluated in a holistic manner together with the inactivation kinetics curves, the scientific rationale for indicator virus selection, and the overall soundness of the validation protocol design. For gene therapy products, special attention should be paid to the cumulative clearance capacity across all process steps to ensure that the overall viral safety profile is at an acceptable level.

Application and Challenges of Nanofiltration

Virus-retentive filtration (nanofiltration) is a critical viral clearance step in downstream purification of gene therapy products. Typical virus-retentive filters have a pore size of approximately 20 nm. The viral clearance mechanism of nanofiltration is primarily size-based exclusion, and it can effectively remove most viruses larger than the membrane pore size, including non-enveloped small parvoviruses such as MVM and PPV.

However, nanofiltration for gene therapy products faces unique challenges: the size of AAV vectors (approximately 20–26 nm) is similar to that of certain indicator viruses (e.g., MVM, 18–26 nm), which may result in reduced vector recovery; empty capsids may affect filtration flux and viral retention efficiency; sample viscosity may increase significantly with vector concentration. Therefore, SDM design for nanofiltration validation should fully account for the effects of vector particle size distribution and empty capsid content on filtration performance, and consideration should be given to using nanofiltration membranes with larger pore sizes as appropriate.

Viral Clearance Evaluation of Chromatography Steps

Ion exchange chromatography (IEX) is a core step in AAV product purification processes, typically employing nuclease digestion followed by anion exchange chromatography (AEX) to capture empty and defective capsids, or cation exchange chromatography (CEX) for fine purification of full capsids. Viral clearance mechanisms in chromatography steps include size exclusion, electrostatic interactions, affinity interactions, and other factors. Discussions at the FDA 2023 Viral Clearance Symposium highlighted that viral clearance efficacy of chromatography steps is influenced by multiple factors, including loading capacity, pH, conductivity, and resin cycling; a multi-factor orthogonal design approach should be adopted for comprehensive evaluation.

Viral Safety Control in Continuous Manufacturing

The newly added Chapter 7 of ICH Q5A(R2) sets out specific requirements for viral safety evaluation in continuous manufacturing. For gene therapy products, continuous manufacturing has become an important development direction, but it also introduces new viral safety challenges. Viral safety control strategies in continuous manufacturing include: in-line virus barrier filters as critical containment measures; appropriate design of residence times and process flows; incorporation of inactivation steps with defined hold times; and enhanced application of process analytical technology (PAT) for real-time monitoring of critical process parameters.